. . . . . . . . "Cephalon est une entreprise am\u00E9ricaine filiale de la soci\u00E9t\u00E9 isra\u00E9lienne Teva Pharmaceutical Industries. Elle fait partie de l'indice NASDAQ-100"@fr . . . . "Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., neuroscientist Michael Lewis, and organic chemist James C. Kauer\u2014all three former scientists with the DuPont Company. Baldino served as Cephalon's chairman and chief executive officer, until his death in December 2010. The company's name comes from the adjective \"cephalic\" meaning \"related to the head or brain\", as it was established primarily to pursue treatments for neurodegenerative diseases. As noted by fundinguniverse.com, in its early years, \"Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.\" Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006. Sales revenues reached $2.8 billion in 2010, ranking Cephalon among the leading biopharmaceutical companies in the world at that time. On May 2, 2011, Teva Pharmaceutical Industries announced it would acquire Cephalon."@en . "Cephalon, Inc."@en . . . . "Cephalon, Inc."@ca . . . . . . . . . "Michael Lewis"@en . . "Cephalon, Inc."@en . . . . "1987"^^ . . . "Cephalon, Inc. war ein US-amerikanisches Pharmaunternehmen. Das 1987 gegr\u00FCndete Unternehmen wurde 2011 vom israelischen Pharmakonzern Teva \u00FCbernommen."@de . . . . . . . . . . . . "--12-31"^^ . "\u0634\u0631\u0643\u0629 \u0633\u064A\u0641\u0627\u0644\u0648\u0646 (\u0628\u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064A\u0629: Cephalon, Inc.) \u0643\u0627\u0646\u062A \u0634\u0631\u0643\u0629 \u0635\u064A\u062F\u0644\u0627\u0646\u064A\u0629 \u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u0645\u0642\u0631\u0647\u0627 \u0641\u064A \u060C \u0628\u0646\u0633\u064A\u0644\u0641\u0627\u0646\u064A\u0627\u060C \u0627\u0633\u062A\u062D\u0648\u0630\u062A \u0639\u0644\u064A\u0647\u0627 \u0634\u0631\u0643\u0629 \u062A\u064A\u0641\u0627 \u0641\u064A \u0645\u0627\u064A\u0648 2011 \u0628\u0635\u0641\u0642\u0629 \u0628\u0644\u063A\u062A 6.8 \u0645\u0644\u064A\u0627\u0631 \u062F\u0648\u0644\u0627\u0631 \u0623\u0645\u0631\u064A\u0643\u064A."@ar . . . "Subsidiary of Teva Pharmaceutical Industries"@en . "alertness drug Provigil, the painkiller Actiq, seizure medication Gabitril"@en . . . . . . "7925018"^^ . . . . . . "Cephalon, Inc. era una empresa biofarmac\u00E8utica amb seu a a l'estat de Pennsilv\u00E0nia als Estats Units. La companyia era especialitzada en els camps de la neurologia, analg\u00E8sica i oncologia. La companyia va ser creada el 1987 pel neur\u00F2leg Frank Baldino. El 2010 va adquirir el fabricant su\u00EDs de gen\u00E8rica Mepha del grup Merckle. El 2011 tenia uns 3700 empleats. El 2011 la companyia israeliana Teva, especialista en medicaments gen\u00E8rics al seu torn va adquirir Cephalon. Tenia una filial a Sant Cugat del Vall\u00E8s."@ca . . . . . . . . "\u0633\u064A\u0641\u0627\u0644\u0648\u0646"@ar . . . . . . . "Cephalon est une entreprise am\u00E9ricaine filiale de la soci\u00E9t\u00E9 isra\u00E9lienne Teva Pharmaceutical Industries. Elle fait partie de l'indice NASDAQ-100"@fr . . . . . "1118939512"^^ . . "James C. Kauer"@en . . . . . . . . "Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., neuroscientist Michael Lewis, and organic chemist James C. Kauer\u2014all three former scientists with the DuPont Company. Baldino served as Cephalon's chairman and chief executive officer, until his death in December 2010. The company's name comes from the adjective \"cephalic\" meaning \"related to the head or brain\", as it was established primarily to pursue treatments for neurodegenerative diseases. As noted by fundinguniverse.com, in its early years,"@en . . . . . . . . . . . "3726"^^ . . "Cephalon (Unternehmen)"@de . . . . . . . . . . . . . . . "J. Kevin Buchi, CEO"@en . . . . . . "* Frank Baldino"@en . . . . . "Cephalon, Inc. era una empresa biofarmac\u00E8utica amb seu a a l'estat de Pennsilv\u00E0nia als Estats Units. La companyia era especialitzada en els camps de la neurologia, analg\u00E8sica i oncologia. La companyia va ser creada el 1987 pel neur\u00F2leg Frank Baldino. El 2010 va adquirir el fabricant su\u00EDs de gen\u00E8rica Mepha del grup Merckle. El 2011 tenia uns 3700 empleats. El 2011 la companyia israeliana Teva, especialista en medicaments gen\u00E8rics al seu torn va adquirir Cephalon. Tenia una filial a Sant Cugat del Vall\u00E8s."@ca . "Cephalon"@en . . . . . . . . . . "Cephalon"@fr . . . . . . . . "14447"^^ . . . . . . . "Cephalon, Inc. war ein US-amerikanisches Pharmaunternehmen. Das 1987 gegr\u00FCndete Unternehmen wurde 2011 vom israelischen Pharmakonzern Teva \u00FCbernommen."@de . "\u0634\u0631\u0643\u0629 \u0633\u064A\u0641\u0627\u0644\u0648\u0646 (\u0628\u0627\u0644\u0623\u0644\u0645\u0627\u0646\u064A\u0629: Cephalon, Inc.) \u0643\u0627\u0646\u062A \u0634\u0631\u0643\u0629 \u0635\u064A\u062F\u0644\u0627\u0646\u064A\u0629 \u0623\u0645\u0631\u064A\u0643\u064A\u0629 \u0645\u0642\u0631\u0647\u0627 \u0641\u064A \u060C \u0628\u0646\u0633\u064A\u0644\u0641\u0627\u0646\u064A\u0627\u060C \u0627\u0633\u062A\u062D\u0648\u0630\u062A \u0639\u0644\u064A\u0647\u0627 \u0634\u0631\u0643\u0629 \u062A\u064A\u0641\u0627 \u0641\u064A \u0645\u0627\u064A\u0648 2011 \u0628\u0635\u0641\u0642\u0629 \u0628\u0644\u063A\u062A 6.8 \u0645\u0644\u064A\u0627\u0631 \u062F\u0648\u0644\u0627\u0631 \u0623\u0645\u0631\u064A\u0643\u064A."@ar . . . . . . . . . .